Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Mortality Trends in Lymphoid and Hematopoietic Malignancies With Circulatory-System Disease Involvement in the United States, 1999-2024

HL - 825

Mortality Trends in Lymphoid and Hematopoietic Malignancies With Circulatory-System Disease Involvement in the United States, 1999-2024

Madho Mal

Poster Presenter: Madho Mal

Thumbnail for Mortality Trends in Older Adults With Myelodysplastic Syndromes and Cardiovascular Disease: A CDC WONDER Analysis (1999-2025)

MDS - 154

Mortality Trends in Older Adults With Myelodysplastic Syndromes and Cardiovascular Disease: A CDC WONDER Analysis (1999-2025)

Priyanka Keshav Lal

Poster Presenter: Priyanka Keshav Lal

Thumbnail for Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

MM - 1329

Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

Chanchal Maheshwari

Poster Presenter: Chanchal Maheshwari

$Thumbnail for Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups$

ABCL - 438

Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups

Jason Westin

Poster Presenter: Jason Westin

Thumbnail for MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

AML - 971

MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

Sai Mourya Meda

Poster Presenter: Sai Mourya Meda

Thumbnail for MRD-Guided Risk Stratification in Venetoclax-Treated Newly Diagnosed AML: A Pooled Survival Analysis

AML - 1351

MRD-Guided Risk Stratification in Venetoclax-Treated Newly Diagnosed AML: A Pooled Survival Analysis

Nuri Tamanna

Poster Presenter: Nuri Tamanna

Thumbnail for MRD-Guided vs Fixed-Duration Targeted Therapy in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Progression-Free Survival and Depth of Response

CLL - 250

MRD-Guided vs Fixed-Duration Targeted Therapy in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Progression-Free Survival and Depth of Response

Sameer Bhimani

Poster Presenter: Sameer Bhimani

Thumbnail for Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

AML - 1483

Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

Paloma Resende

Poster Presenter: Paloma Resende

Thumbnail for Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

MDS - 819

Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

Jeremiah Bearss

Poster Presenter: Jeremiah Bearss

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.